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Disruption of human fetal testis development is
widely accepted to underlie testicular germ cell can-
cer (TGCC) origin and additional disorders within
testicular dysgenesis syndrome (TDS). However,
the mechanisms for the development of testicular
dysgenesis in humans are unclear. We used ex vivo
culture and xenograft approaches to investigate the
importance of Nodal and Activin signaling in human
fetal testis development. Inhibition of Nodal, and to
some extent Activin, signaling disrupted seminifer-
ous cord formation, abolished AMH expression,
reduced androgen secretion, and decreased gono-
cyte numbers. Subsequent xenografting of testicular
tissue rescued the disruptive effects on seminiferous
cords and somatic cells but not germ cell effects.
Stimulation of Nodal signaling increased the number
of germ cells expressing pluripotency factors, and
these persisted after xenografting. Our findings sug-
gest a key role for Nodal signaling in the regulation of
gonocyte differentiation and early human testis
development with implications for the understanding
of TGCC and TDS origin.
INTRODUCTION
Sex-specific differentiation of bipotential fetal gonads involves a
complex interplay of signaling cascades, which direct cell line-
age specification and establishment of the somatic cell niche
appropriate for testis or ovary development (Rotgers et al.,
2018). The differentiation of germ cells in both sexes is directed
by cues from the somatic cells that trigger differentiation in either
themale or female direction, resulting ultimately in spermatogen-1924 Cell Reports 25, 1924–1937, November 13, 2018 ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://esis or oogenesis. The regulation of somatic cell differentiation
and commitment of the germ cell lineage in the human fetal testis
is not well understood. There are many similarities, but also clear
differences compared to mice, from which the majority of the
current knowledge on mammalian early gonad development
has been established. Human testis differentiation is initiated
around gestational week (GW) 6, when the primordial germ cells
have arrived in the bipotential gonad and become surrounded by
somatic precursor cells. Expression of SRY and SOX9 is initi-
ated, resulting in the differentiation of Sertoli cells and enclosing
of germ cells (at this stage called gonocytes) within seminiferous
cords (Sinclair et al., 1990; Berta et al., 1990; Hanley et al., 2000).
The organization of seminiferous cords is initiated at approxi-
mately GWs 7–8, with cords clearly present from GWs 9–10.
The interstitial cell populations, including fetal Leydig cells, pro-
genitors of adult Leydig cells, and progenitors of peritubular my-
oid cells are also established at the same time (Ostrer et al.,
2007). The somatic cell niche in the fetal testes is organized to
ensure optimal support of the germ cells, including at this early
developmental time point a high proliferation rate of gonocytes
(Bendsen et al., 2003) and prevention of gonocytes entering
meiosis (Jørgensen and Rajpert-De Meyts, 2014).
Gonocytes in the human fetal testis are characterized by the
expression of pluripotency factors, including OCT4, NANOG,
and AP2g, which are gradually downregulated in an asynchro-
nous manner, starting at approximately GWs 16–20, thereby
marking the transition from gonocyte to pre-spermatogonium
(Jørgensen et al., 1995; Hoei-Hansen et al., 2004; Gaskell et al.,
2004; Rajpert-De Meyts et al., 2004; Honecker et al., 2004; Pauls
et al., 2006; Mitchell et al., 2008). The pre-spermatogonial popu-
lation can be distinguished from gonocytes by the expression of
MAGE-A4, distinct morphology, and their localization closer
to the basement membrane within the seminiferous tubule
compared to gonocytes (Rajpert-de Meyts and Hoei-Hansen,
2007). This transition from germ cells expressing pluripotency
factors to amoredifferentiated phenotype is a key event in normaluthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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perinatal testis development, and the disruption of this transition
mayhaveconsequences later in life.Prematuregermcell differen-
tiationmay result in germcell loss,with potential effects on fertility
in adult life, while failure to differentiate can result in an arrested
gonocyte population, which develops into testicular germ cell
cancer precursor cells, called germ cell neoplasia in situ (GCNIS,
previously known as carcinoma in situ). GCNIS cells develop into
malignant testicular germ cell tumors in young adulthood (Skak-
kebaek et al., 2016; Rajpert-De Meyts et al., 2016).
Themolecular mechanisms directing the transition from gono-
cyte to pre-spermatogonium are currently not characterized in
detail in humans, but recent studies in mice have demonstrated
a role for Nodal and Activin signaling in the regulation of pluripo-
tency factor expression in early embryonic germ cell differentia-
tion (Souquet et al., 2012; Spiller et al., 2012; Wu et al., 2013;
Miles et al., 2013). Nodal and Activin both signal through binding
to a receptor complex consisting of ActRII and ALK4/7, with
Nodal also requiring the presence of the co-receptor Cripto.
Binding and activation of these receptor complexes lead to the
phosphorylation of Smad2/3, which regulates the transcription
of target genes that for Nodal signaling includes Nodal itself,
as well as its endogenous inhibitor Lefty (Papanayotou and Col-
lignon, 2014; Spiller et al., 2017). Activation of SMAD2/3 via
transforming growth factor b (TGF-b), Activin or Nodal signaling
is necessary for the maintenance of pluripotency in human em-
bryonic stem cells (James et al., 2005), which implicates these
pathways as possible regulators of the expression of pluripo-
tency factors in human fetal gonocytes. Nodal and Activin
signaling have also been implicated in the prevention of prema-
ture meiotic entry of germ cells in mice (Souquet et al., 2012; Wu
et al., 2013; Miles et al., 2013) and in the formation of testicular
cords during mouse testis differentiation (Wu et al., 2013; Miles
et al., 2013). Because the occurrence of GCNIS cells in humans
often coincides with focal testicular dysgenesis (Hoei-Hansen
et al., 2003), it raises the possibility of a role for Nodal and/or
Activin dysfunction in the origin of testicular dysgenesis syn-
drome (TDS). Testicular dysgenesis syndrome comprises a
group of disorders that include GCNIS, testicular germ cell can-
cer, cryptorchidism, and some forms of hypospadias and
infertility, which result from abnormal fetal testis developmentFigure 1. Effects of Simultaneous Inhibition of Nodal and Activin Signa
Morphology, Germ Cell Number, and Somatic Cell Function
(A) Experimental overview of SB431542 (ALK4/5/7 inhibitor) treatment resulting in
fetal testis samples from first trimester during 14 days of culture. DPBS, Dulbecc
(B) Morphology and expression pattern of germ cell markers OCT4 (gonocytes) an
(20 mM) for 2 weeks in ex vivo culture. Tissue from nine fetuses was investigated
(C) Quantification of germ cells determined as the number of OCT4+ gonocytes p
difference compared to vehicle control, ***p < 0.001.
(D) Expression pattern of somatic cell markers, including SOX9 and AMH (Sertoli c
nine fetuses was investigated. Counterstaining with Mayer’s hematoxylin; scale
(E) Quantification of AMH produced by the fetal testis in ex vivo culture and secre
culture period and was pooled for each individual tissue piece. AMH was measu
represent means ± SEMs, with n = 7. Significant difference compared to vehicle
(F) Quantification of COUP-TFII positive cells per square millimeter. Values repr
control, ***p < 0.001.
(G) Quantification of androgens produced in the fetal testis ex vivo cultures and se
14-day culture period and was pooled for each individual tissue piece. Androgen
MS/MS) and are shown as ratios compared to corresponding vehicle controls. V
vehicle control, *p < 0.05, **p < 0.01, and ***p < 0.001.
1926 Cell Reports 25, 1924–1937, November 13, 2018(Skakkebaek et al., 2001, 2016). In this study, we sought to
investigate the role of Nodal and Activin signaling in human fetal
testis development by examining the consequences of experi-
mentally manipulating these signaling pathways at different
developmental time points. Our study demonstrates that the
Nodal pathway plays a key role in the regulation of pluripotency
factor expression in human gonocytes and in the establishment
of the seminiferous cords. In addition to the distinct Nodal-medi-
ated events in human testicular development, there are overlap-
ping roles of Nodal signaling and Activin signaling involved in
mediating normal human fetal testis development, including
anti-M€ullerian hormone (AMH) secretion, fetal germ cell survival,
and steroidogenesis.
RESULTS
Nodal and Activin Signaling Factors Are Expressed in
Human Fetal Testis
To establish the presence and expression level of key factors in
the Nodal and Activin signaling pathways in human fetal testis,
qPCR was conducted. Testis samples from the first and second
trimesters and ovary samples from the first trimester were
included in the analysis. All of the investigated factors (ALK4,
ALK5, ALK7, ACVR2B, NODAL, CRIPTO, LEFTY, INHBA,
INHBB) involved in Nodal and Activin signaling were expressed
in human fetal testis and ovary samples from the first trimester
and in testis samples from the second trimester, each with a
distinct expression pattern (Figure S1). The only exception was
ALK7, which was detectable in only 3 of 40 investigated sam-
ples. The observed expression pattern is consistent with both
Nodal and Activin signaling playing a role in human fetal testis
development.
Effects of SB431542 Exposure on Germ Cells in Human
First Trimester Testis Cultures
To examine the role of Nodal and Activin signaling in fetal
testis development, isolated first trimester fetal testis tissue
was cultured in the presence of the specific ALK4/5/7 inhibitor
SB431542 for 2 weeks (Figure 1A). This simultaneous inhibi-
tion of Nodal signaling and Activin signaling resulted in theling in First Trimester Human Fetal Testis Ex Vivo Culture on Overall
the simultaneous inhibition of Nodal and Activin signaling pathways in human
o’s PBS.
dMAGE-A4 (pre-spermatogonia) in fetal testis samples treated with SB431542
. Counterstaining with Mayer’s hematoxylin; scale bar corresponds to 50 mm.
er square millimeter. Values represent means ± SEMs, with n = 9. Significant
ells), COUP-TFII (interstitial cells), and CYP11A1 (fetal Leydig cells). Tissue from
bar corresponds to 50 mm.
ted into the media. Medium was collected every 48 hr throughout the 14-day
red by ELISA and is shown as the ratio compared to vehicle controls. Values
control, *p < 0.05.
esent means ± SEMs, with n = 7. Significant difference compared to vehicle
creted to the media droplets. Media was collected every 48 hr throughout the
s were measured by liquid chromatography-tandem mass spectrometry (LC-
alues represent means ± SEMs, with n = 7. Significant difference compared to
near-complete loss of OCT4+ gonocytes in fetal testes explants
(Figure 1B), as confirmed by their quantification (p < 0.001; Fig-
ure 1C). To determine whether this was due to specific downre-
gulation of OCT4 or a general downregulation of pluripotency
factors, the expression of additional pluripotency-related pro-
teins was investigated, including NANOG, AP2g, SALL4,
LIN28, and C-KIT. None of these additional pluripotency factors
was expressed (except in a few cells, data not shown) in fetal
testes samples cultured with SB431542, thus resembling the
finding for OCT4. These observations did not distinguishwhether
SB431542 treatment resulted in the specific downregulation of
pluripotency factors, premature differentiation of germ cells
(with a resulting downregulation of pluripotency factors), or
loss of the gonocyte population due to apoptosis or reduced pro-
liferation. We ruled out the possibility that SB431542 treatment
accelerated gonocyte differentiation by showing that only very
few germ cells expressing MAGE-A4 (marker of pre-spermato-
gonia) were present in fetal testes cultures (Figure 1B). The
lack of accelerated gonocyte differentiation was confirmed by
the observation that no VASA+ cells could be detected in fetal
testes treated with SB431542, and no indication of SB431542-
mediated premature initiation of meiosis was found based on
the lack of SCP3+ cells (Figure S2A). However, it is not possible
to completely exclude that pluripotency factors are downregu-
lated by SB431542 exposure as the first step in differentiation,
without upregulation of MAGE-A4; as such, an OCT4/MAGE-
A4 subpopulation of germ cells has been described previously
(Gaskell et al., 2004).
All cell types in the fetal testis cultures continuedproliferation in
both vehicle- and SB431542-treated samples, as assessed by
the incorporation of bromodeoxyuridine (BrdU) at the end of the
culture period (14 days) and after 7 days of culture (Figure S3A).
The number of proliferating (BrdU+) gonocytes per square milli-
meter was significantly (p < 0.001) reduced in SB431542-treated
fetal testis compared to vehicle controls (Figure S3B), which is in
line with the overall reduced number of gonocytes (OCT4+) de-
tected in these samples (Figure 1C). Only a few apoptotic (cleav-
age product of poly-ADP-ribose polymerase-positive [cPARP+])
cells were detected after 7 and 14 days of culture, regardless of
treatment (Figure S3A); despite this, a significantly higher number
of cPARP+ cells per squaremillimeter were found after 14 days of
culture in samples treated with SB431542 (Figure S3B). The
observation of increased apoptosis in SB431542-treated fetal
testes was confirmed by terminal deoxynucleotidyl transferase
deoxyuridine triphosphate nick end labeling (TUNEL) staining,
withmore TUNEL+ cells detected after both 7 and 14 days of cul-
ture (Figure S3A). These findings suggest that the reduction in
gonocyte numbers in SB431542-treated fetal testis samples
was the combined result of reduced proliferation and increased
apoptosis during the culture period resulting from the simulta-
neous inhibition of Nodal and Activin signaling.
Effects of SB431542 Exposure on Somatic Cell Function
in Human First Trimester Testis Cultures
To evaluate the effects of SB431542 treatment on somatic cell
function, the histology of cultured first trimester fetal testes
was evaluated, and a panel of immunohistochemical markers
was used to evaluate key aspects of somatic cell function. Themost pronounced effect of SB431542 treatment was that it dis-
rupted normal seminiferous cord structure (Figure 1D), which
was in contrast to the cultured vehicle control samples that
showed normal fetal testis morphology (Figure 1D). Sertoli cells
were clearly present in the SB431542-treated samples based
on the expression of SOX9. However, their normal expression
of AMH was completely abolished at the end of the culture
period (Figure 1D). This observation was confirmed by the quan-
tification of AMH secreted into the media during the 14-day cul-
ture period, which was significantly reduced (p < 0.05) in fetal
testis cultures treated with SB431542 compared to vehicle con-
trols (Figure 1E). This indicates that the Sertoli cells were affected
either directly by the SB431542 treatment, indirectly by the
reduced number of germ cells present, or through the disruption
of the seminiferous cord structure. To determine whether the
Sertoli cells had transdifferentiated toward a female granulosa-
like cell type, the expression of FOXL2 was examined, but no
positive cells were detected in either SB431542- or vehicle-
treated fetal testis samples (Figure S2B). In the interstitial
compartment, cells expressing chicken ovalbumin upstream
promoter-transcription factor II (COUP-TFII) (mesenchymal and
adult Leydig cells progenitors) and CYP11A1 (fetal Leydig cells)
immunopositive cells were present in SB431542-exposed cul-
tures, but the number of especially COUP-TFII+ cells appeared
to be reduced when compared to vehicle control samples (Fig-
ure 1D). This observation was confirmed after quantification,
wherein a significantly lower (p < 0.001) number of COUP-TFII+
cells per square millimeter were found in SB431542-treated
samples (Figure 1F). In view of these observations, we evaluated
whether fetal Leydig cells in SB431542-exposed testis cultures
had altered steroidogenic function. Analysis of media from
ex vivo cultures revealed that the secretion of testosterone and
androstenedione were significantly reduced (p < 0.05 and
p < 0.01, respectively) following SB431542 exposure (Figure 1G).
In contrast, the level of early precursors in the steroidogenic
pathway, namely 17-hydroxyprogesterone and progesterone
were significantly (p < 0.001) elevated in SB431542-exposed
samples compared to vehicle controls (Figure 1G), indicating
treatment-related inhibition of CYP17A1 activity. These results
suggest that the simultaneous inhibition of Nodal and Activin
signaling in first trimester fetal testes disrupts seminiferous
cord structure and impairs the normal function of both Sertoli
and Leydig cells, the two key somatic cell types in the fetal testis.
Long-Term Effects of SB431542 Exposure in First
Trimester Fetal Testes
To examine whether the adverse effects of SB431542 treatment
in culture were permanent or recoverable, we cultured first
trimester fetal testes for 6 days ±SB431542 and then xeno-
grafted the cultured tissue into castrated nude mice for 6 weeks
without any additional treatment (Figure 2A). Following the
6-week grafting period, the majority of the effects observed after
6 days of SB431542 treatment appeared to have been rescued,
except for the SB431542-induced loss of OCT4+ gonocytes,
because their numbers were significantly (p < 0.05) reduced
both after 6 days’ culture and after xenografting (Figures 2B
and 2C). The seminiferous cords and the interstitial compartment
appeared grossly normal after grafting of fetal testis tissue thatCell Reports 25, 1924–1937, November 13, 2018 1927
Figure 2. Long-Term Effects of Simultaneous Inhibition of Nodal and Activin Signaling in Human Fetal Testes from the First Trimester
(A) Experimental overview of treatment with SB431542 for 6 days in ex vivo culture, followed by xenografting for 6 weeks (without treatment).
(B) Effects of initial short-term treatment with SB431542 (20 mM) followed by xenografting on tissue morphology and expression of germ cell and somatic cell
markers in first trimester fetal testis samples. Cultured and grafted samples (±SB431542) are compared to samples from the same fetus, which has only been
cultured ex vivo (±SB431542). Immunohistochemical staining include OCT4 and MAGE-A4 (germ cell markers), AMH (Sertoli cell marker), COUP-TFII (marker of
(legend continued on next page)
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had been initially exposed to SB431542 in culture. Moreover, the
expression level and pattern of AMH, COUP-TFII, and CYP11A1
were unaltered compared to the corresponding vehicle control
group following xenografting (Figure 2B). However, the initial
SB431542 exposure in ex vivo culture exerted long-term effects
on Leydig cell steroidogenesis, as shown by a significant
(p < 0.05) decrease in host mouse seminal vesicle weight (in cas-
trated mice, this is a readout of testosterone production from the
xenografted tissue during the grafting period) and the significant
(p < 0.05) reduction in serum testosterone levels in host mice
(Figure 2D).
Long-Term Effects of SB431542 Exposure in Second
Trimester Fetal Testes
To investigate whether SB431542 treatment of second trimester
fetal testes in ex vivo culture resulted in effects resembling those
observed in first trimester samples, a similar experimental setup
was used with 6 days’ SB431542 exposure in culture, followed
by grafting of tissue pieces for 6 weeks (Figure 2A). In second
trimester fetal testis samples, the germ cell population is a
mixture of gonocytes (OCT4+) and pre-spermatogonia (MAGE-
A4+). Following SB431542 exposure for 6 days in ex vivo culture,
the number of gonocytes was severely reduced (p < 0.05) (Fig-
ures 3A and 3B). Furthermore, morphological evaluation re-
vealed that a subpopulation of the pre-spermatogonia appeared
abnormal (multinucleated) (Figures 3A and S4). Quantification of
the number of pre-spermatogonia showed a significant reduc-
tion (p < 0.05) after the xenografting period in samples initially
treated with SB431542. Also, the total number of germ cells
per area (OCT4+ + MAGE-A4+) was significantly reduced
(p < 0.05) after SB431542 exposure in ex vivo culture and an
even larger reduction in numbers was observed following the
xenografting period (Figure 3B). These results suggest that
simultaneous SB431542-mediated inhibition of Nodal signaling
and Activin signaling severely reduces the number of germ cells
in second trimester fetal testes, with effects on both gonocyte
and pre-spermatogonia populations.
The effects of SB431542 treatment on somatic cell function in
second trimester testes were less evident compared to first
trimester fetal testis tissue. After 6 days’ exposure of second
trimester fetal testes to SB431542, the seminiferous cord struc-
ture appeared normal, as did the expression of Sertoli cell
markers AMH and SOX9 (Figure 3A). In contrast, both Leydig
cells and peritubular myoid cells were affected, with only a few
CYP11A1+ Leydig cells evidently present in the interstitium,
and an apparent loss of morphologically distinct peritubular
myoid cells was observed (Figure 3A). After grafting of the tissue
for 6 weeks, the Leydig cells (based on CYP11A1 expression)
and the peritubular myoid cells (based on COUP-TFII expres-
sion) appeared similar between the initially SB431542- andinterstitial cells), and CYP11A1 (fetal Leydig cell marker). Counterstaining with M
fluorescence with OCT4 (red), MAGE-A4 (green), and SOX9 (Sertoli cell marker,
(C) Quantification of germ cells per square millimeter was determined as the numb
Significant difference compared to vehicle controls, *p < 0.05.
(D) Testosterone production by the first trimester fetal testis tissue grafted into c
vehicle controls and testosterone levels (ng/mL) in mouse serum determined by ra
difference compared to vehicle controls, *p < 0.05.vehicle-exposed samples (Figure 3A). In keeping with the normal
expression of CYP11A1 after the xenografting period, there was
no difference in the level of serum testosterone at the end of the
grafting period between mice xenografted with SB431542- and
vehicle-exposed testis tissue (Figure 3C). However, significantly
lower seminal vesicle weight was found in mice grafted with
testis tissue initially exposed to SB431542, implying that testos-
terone production during the grafting period may have initially
been reduced as it was for equivalent first trimester samples,
but that the testosterone production recovered during the xeno-
grafting period.
Separating Effects of Nodal andActivin Signaling in First
Trimester Testis Cultures
The effects of SB431542 described above could be due to the
inhibition of Nodal, Activin, and/or growth differentiation factor
(GDF) signaling, although based on previous studies in fetal
mice testes, the effects are most likely mediated via Nodal or
Activin pathways (Spiller et al., 2012; Souquet et al., 2012; Wu
et al., 2013; Miles et al., 2013). To determine the relative contri-
bution of Nodal and Activin signaling, experiments were con-
ducted to inhibit or stimulate the two pathways separately
(Figure 4A). Activin signaling was stimulated by treatment with
recombinant Activin A and inhibited with follistatin, while Nodal
signaling was stimulated by treatment with recombinant Nodal
and inhibited by Lefty.
Inhibition of Nodal signaling by Lefty treatment in first trimester
fetal testis ex vivo cultures resulted in effects resembling those
observed after simultaneous inhibition of Nodal and Activin (Fig-
ure 4B). Treatment with Lefty appeared to reduce the number of
OCT4+ gonocytes, disrupted seminiferous cord structures, and
reduced AMH expression (Figure 4B). The effects of Nodal inhi-
bition alone were less severe compared to SB431542-treated
samples, but the inhibition of Nodal signaling was likely the
main driver of the severe morphological changes and disruption
of seminiferous cord formation that were observed after simulta-
neous inhibition of Nodal and Activin signaling with SB431542
(Figure 4B). In accordance, inhibition of the Activin pathway in
cultures of first trimester fetal testis did not result in any major
testicular effects on morphology or the expression pattern of
germ cell, Sertoli cell, or interstitial cell markers (Figure S5).
The quantification of gonocytes in Lefty-treated fetal testis
samples confirmed that a significantly (p < 0.05) lower number
of OCT4+ cells per square millimeter were present (Figure 5A),
suggesting a role for Nodal signaling in germ cell survival. Stim-
ulation of Nodal signaling in ex vivo cultures of first trimester fetal
testes resulted in a significant (p < 0.05) increase in the number of
OCT4+ gonocytes compared to vehicle controls (Figure 5A), as
well as a significant (p < 0.05) increase in AMH secretion
compared to vehicle controls (Figure 5B). No effects on grossayer’s hematoxylin; scale bar corresponds to 50 mm. Bottom: triple immuno-
blue). Tissue from three fetuses was investigated.
er of OCT4+ and MAGE-A4+ cells. Values represent means ± SEMs, with n = 3.
astrated nude mice. Seminal vesicle weight calculated as a ratio compared to
dioimmunoassay (RIA). Values represent means ± SEMs, with n = 3. Significant
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Figure 3. Long-Term Effects of Simultaneous Inhibition of Nodal and Activin Signaling in Second Trimester Human Fetal Testes
A) Effects of initial short-term (6 days) treatment with SB431542 (20 mM), followed by xenografting for 6 weeks (without treatment) on tissue morphology and
expression of germ cell and somatic cell markers in second trimester fetal testis samples. Cultured and grafted samples (±SB431542) are compared to samples
from the same fetus, which has been cultured only ex vivo (±SB431542). Immunohistochemical staining include OCT4 and MAGE-A4 (germ cell markers), AMH
(Sertoli cell marker), COUP-TFII (marker of interstitial cells), and CYP11A1 (fetal Leydig cell marker). Counterstaining with Mayer’s hematoxylin; scale bar cor-
responds to 50 mm. *Multinucleated germ cell; see also higher-magnification image in Figure S4. Bottom: triple immunofluorescence with OCT4 (red), MAGE-A4
(green), and SOX9 (Sertoli cell marker, blue). Tissue from five fetuses was investigated.
(B) Quantification of germ cells was determined as the number of gonocytes (OCT4+) per square millimeter, pre-spermatogonia (MAGE-A4+) per square milli-
meter, and total number of germ cells (OCT4+ +MAGE-A4+) per squaremillimeter. Values represent means ±SEMs, with n = 5. Significant difference compared to
vehicle controls, *p < 0.05.
(C) Testosterone production by the second trimester fetal testis tissue grafted into castrated nudemice. Seminal vesicle weight calculated as a ratio compared to
vehicle controls and testosterone levels (ng/mL) inmouse serum determined by RIA. Values represent means ±SEMs, with n = 5. Significant difference compared
to vehicle controls, *p < 0.05.morphology and overall expression of Sertoli cell or interstitial
cell markers, cell proliferation, or apoptosis were found after
Nodal treatment (Figures 4B and S6). In contrast, stimulation of
Activin signaling in fetal testis cultures did not affect the number
of OCT4+ gonocytes or AMH secretion (Figures 5C and 5D).1930 Cell Reports 25, 1924–1937, November 13, 2018Inhibition of the Activin pathway following follistatin treatment re-
sulted in a significantly (p < 0.05) lower number of OCT4+ cells
per square millimeter (Figure 5C), while no effect on AMH secre-
tion was found (Figure 5D). These findings suggest an overlap-
ping function of Nodal and Activin pathways in mediating germ
Figure 4. Effects of Manipulating Nodal Signaling in First Trimester
Fetal Testis Ex Vivo Cultures
(A) Experimental overview of treatment with recombinant Nodal (50 ng/mL),
Lefty (100 ng/mL), Activin A (50 ng/mL), and follistatin (100 ng/mL) for 14 days
in ex vivo culture of human fetal testes.
(B)Morphology and expression pattern of germ cell markersOCT4 (gonocytes)
and MAGE-A4 (pre-spermatogonia), Sertoli cell marker (AMH), interstitial cell
marker (COUP-TFII), and fetal Leydig cell marker (CYP11A1) investigated in
first trimester fetal testis samples treatedwith Nodal and Lefty. n = 7 fetuses for
Nodal treatment and n = 12 for Lefty treatment. Counterstaining with Mayer’s
hematoxylin; scale bar corresponds to 50 mm.cell survival in fetal testis. Stimulation of the Nodal pathway also
affected androgen production, with significantly (p < 0.05) higher
levels of androstenedione and dehydroepiandrosterone sulfate
(DHEAS) and significantly (p < 0.05) lower levels of 17-hydroxy-
progesterone (17-OHP) and cortisone compared to vehicle-
treated controls (Figure 5E). In contrast, Lefty treatment did not
affect steroidogenesis (Figure 5E), which is in accordance with
the observed Leydig cell expression of CYP11A1 that appeared
unaltered compared to the vehicle control (Figure 4B).
Manipulation of the Nodal pathway did not appear to affect the
expression of proliferation (BrdU) and apoptosis (cPARP)
markers (Figure S6A), and this observation was confirmed after
the quantification of BrdU+ germ cells and cPARP+ cells per
square millimeter, demonstrating no difference between Nodal
and Lefty treatment compared to vehicle controls (Figure S6B).
Although a tendency toward a lower number of proliferating
germ cells and an increased number of apoptotic cells was found
in Lefty-treated testis samples (Figure 6B), which is in line with
the finding of a reduced number of gonocytes (OCT4+) in fetal
testes following Lefty treatment (Figure 5A). No effects on
apoptosis and proliferation of germ cells were observed after
manipulation of the Activin pathway (Figure S7A), despite a ten-
dency toward a lower number of proliferating germ cells and a
higher number of apoptotic cells after follistatin treatment (Fig-
ure S7B). Also, no effects on steroidogenesis were detected after
Activin and follistatin treatment in fetal testis (Figure S7C). These
results suggest that Nodal signaling is involved in the regulation
of pluripotency factor expression in germ cells, in establishment
of seminiferous cords, and may also play a role in steroidogene-
sis by stimulating androgen production in fetal Leydig cells.
Stimulation of Nodal Signaling in Second Trimester Fetal
Testes
To investigate the long-term consequences of stimulating Nodal
signaling, second trimester fetal testis samples containing a
mixture of gonocytes (OCT4+) and pre-spermatogonia (MAGE-
A4+) were treated with recombinant Nodal for 10 days in
ex vivo culture, followed by xenografting for 6 weeks (Figure 6A).
Again, no apparent effects on morphology, overall expression
of Sertoli cells, or interstitial cell markers were found (Fig-
ure 6B), and there was no difference in serum testosterone
or seminal vesicle weight between host mice grafted with
Nodal-treated samples and mice grafted with vehicle-treated
samples (Figure 6C). Interestingly, OCT4+ gonocytes were pre-
sent in the Nodal-treated samples after xenografting, whereas
very few OCT4+ germ cells were observed in vehicle-treated
control samples, in which the majority of germ cells presentCell Reports 25, 1924–1937, November 13, 2018 1931
Figure 5. Effects of Manipulating Nodal and
Activin Signaling Seperately in First
Trimester Fetal Testis Ex Vivo Cultures
(A) Quantification of gonocytes determined as the
number of OCT4+ cells per square millimeter
in samples treated with recombinant Nodal
(50 ng/mL) and Lefty (100 ng/mL) for 14 days in
ex vivo culture. Values represent means ± SEMs,
with n = 7 (Nodal) and n = 12 (Lefty). *Significant
difference compared to vehicle controls, *p < 0.05.
(B) Quantification of AMH produced by the fetal
testis tissue in ex vivo cultures exposed to Nodal
and Lefty and secreted into the media. Medium
was collected every 48 hr throughout the 14-day
culture period and pooled for each individual tis-
sue piece. AMH was measured by ELISA and is
shown as a ratio compared to vehicle controls.
Values represent means ± SEMs, with n = 7
(Nodal) and n = 12 (Lefty). *Significant difference
(p < 0.05) compared to vehicle controls.
(C) Quantification of gonocytes determined as the
number of OCT4+ cells per square millimeter in
samples treated with recombinant Activin A
(50 ng/mL) and follistatin (100 ng/mL) for 14 days in
ex vivo culture. Values represent means ± SEMs,
with n = 9 (Activin A) and n = 7 (follistatin). Sig-
nificant difference compared to vehicle controls,
*p < 0.05.
(D) Quantification of AMH produced by the fetal
testis tissue in ex vivo cultures exposed to Activin
and follistatin and secreted into the media. AMH
was measured by ELISA and is shown as a ratio
compared to vehicle controls. Values represent
means ± SEMs, with n = 9 (Activin A) and n = 7
(follistatin).
(E) Quantification of androgens produced in the
fetal testis tissue ex vivo cultures and secreted into
the media droplets. Medium was collected every
48 hr throughout the 14 weeks of culture and
pooled for each individual tissue piece. Androgens
were measured by LC-MS/MS and are shown as
ratios compared to the corresponding vehicle
controls for each metabolite. Values represent
means ± SEMs, with n = 7 (Nodal) and n = 12
(Lefty). Significant difference compared to vehicle
controls, *p < 0.05.
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Figure 6. Long-Term Effects of Stimulating the Nodal Signaling Pathway in Second Trimester Human Fetal Testes
(A) Experimental overview of treatment with Nodal for 10 days in ex vivo culture, followed by xenografting for 6 weeks (without treatment).
(B) Effects of initial short-term treatment with Nodal (50 ng/mL), followed by xenografting on tissue morphology and expression of germ cell and somatic cell
markers in second trimester fetal testis samples. Cultured and grafted samples (±Nodal) are compared to samples from the same fetus, which has been cultured
only ex vivo (±Nodal). Immunohistochemical staining include OCT4 andMAGE-A4 (germ cell markers), AMH (Sertoli cell marker), COUP-TFII (marker of interstitial
(legend continued on next page)
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were MAGE-A4+ pre-spermatogonia (Figure 6B). Stimulation of
the Nodal pathway in second trimester fetal testis samples ap-
peared to prevent germ cell differentiation because the total
number of germ cells per area was unaffected when examined
both after ex vivo culture alone or after ex vivo culture and subse-
quent xenografting (Figure 6D). Consequently, the ratio of gono-
cytes to the total number of germ cells was significantly
increased (p < 0.05) in Nodal-stimulated fetal testis tissue after
the xenografting period (Figure 6E). This finding most likely re-
flects a prolonged maintenance of OCT4+ expression in gono-
cytes in fetal testes following the initial stimulation of Nodal
signaling.
DISCUSSION
Despite growing evidence that human fetal testis development
and dysfunction may be a critical determinant of the later risk
of several reproductive disorders included in the testicular
dysgenesis syndrome, the underlying molecular mechanisms
and signaling pathways are largely unknown. The present study
contributed to elucidating this deficiency by combining ex vivo
tissue culture and xenograft approaches, thereby demonstrating
that Nodal and Activin signaling control distinct processes
during human testicular development and male germ cell differ-
entiation, but with some overlap in function between the two
pathways. Our study shows that the Nodal signaling pathway
is involved in regulating the expression of pluripotency factors
in human fetal germ cells and plays a role in the establishment
of seminiferous cords.
We found that simultaneous inhibition of Nodal and Activin
signaling by SB431542 exposure in the cultures of first trimester
fetal testes caused a complete loss of the gonocyte population
and disruption of seminiferous cord formation, reduced the
expression of somatic lineage markers, reduced the secretion
of AMH, and impaired steroidogenesis. Some of these effects
are in accordance with previous results from mouse studies,
including disruption of seminiferous cords and distorted
arrangement of somatic cells, which were found in fetal mouse
testes treated with SB431542 (Wu et al., 2013; Miles et al.,
2013). We found reduced androgen production and accumula-
tion of steroidogenic precursors, consistent with impaired
CYP17A1 activity, but effects on steroidogenesis have not previ-
ously been reported after simultaneous inhibition of Nodal and
Activin signaling. The SB431542-induced loss of gonocytes in
the human fetal testis was more severe compared to the germ
cell effects reported in mice in which only a minor reduction in
germ cell survival and premature initiation of meiosis was found
(Souquet et al., 2012; Wu et al., 2013). Our finding of both
reduced germ cell proliferation and increased apoptosis in fetal
testes treated with SB431542 does not exclude the possibilitycells), and CYP11A1 (fetal Leydig cell marker). Counterstaining with Mayer’s hem
with OCT4 (red), MAGE-A4 (green), and SOX9 (Sertoli cell marker, blue). Tissue f
(C) Testosterone production by the fetal second trimester fetal testis tissue gra
compared to vehicle controls and testosterone levels (ng/mL) in mouse serum d
(D) Quantification of germ cells per square millimeter was determined as the numb
(E) Ratio of gonocytes/total germ cells corresponds to the number of OCT4+ ce
Significant difference compared to vehicle controls, *p < 0.05.
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germ cell population, as was previously reported in a mouse
model with compromised Nodal signaling (Spiller et al., 2012).
However, because we found no parallel increase in the number
of pre-spermatogonia (MAGE-A4+ and/or VASA+) or meiotic
(SCP3+) germ cells after SB431542 exposure, even after xeno-
grafting, it is most likely that the gonocytes had been lost. This
species difference in the effects on germ cells following
manipulation of Nodal signaling could be attributed to different
experimental approaches or differences in the regulation of plu-
ripotency factors, with gradual asynchronous transition from
gonocyte to pre-spermatogonia in humans and a more synchro-
nized germ cell differentiation process in rodents (Mitchell et al.,
2008). Further evidence of dissimilarity in the role of Nodal
signaling between humans and mice is the observation that
Nodal pathway genes are expressed in fetal germ cells in both
testes and ovaries in humans (Li et al., 2017), while expression
is predominantly found in male germ cells in fetal mouse gonads
(Souquet et al., 2012; Spiller et al., 2012; Wu et al., 2013; Miles
et al., 2013).
The majority of the effects observed in first trimester fetal
testes after SB431542-induced simultaneous Nodal and Activin
inhibition were rescued with time after xenografting, including
the re-establishment of seminiferous cords and a normal expres-
sion pattern of somatic cell markers. The exceptions were
the observed effects on androgen production, which was still
reduced after the xenografting period, and the loss of the gono-
cyte population. The latter was not rescued after xenografting,
which is consistent with an initial SB431542-induced loss of
these cells by reduced proliferation and increased apoptosis
rather than there being, for example, downregulation of pluripo-
tency factors without the simultaneous upregulation of more
differentiated germ cell markers. In comparison, the effects of
the simultaneous inhibition of Nodal and Activin signaling in sec-
ond trimester fetal testis samples were less severe than in first
trimester samples, with a reduced number and an altered
morphology of germ cells and a reduced seminal vesicle weight
in mice grafted with SB431542-treated tissue being the main
effects. The androgen production was less affected by the end
of the xenografting period, with no difference in serum testos-
terone between mice grafted with fetal testis tissue initially
treated with SB431542, and vehicle control. The finding of a sub-
population of multinucleated pre-spermatogonia is interesting
because this abnormality has been observed in cryptorchid
boys, some of whom also had GCNIS (Cortes et al., 2003).
Also, multinucleated germ cells are a feature of testicular
dysgenesis syndrome in fetal rats following in utero exposure
to the plasticizer di-n-butyl-phthalate (DBP) and are also
observed in human fetal testis xenografts following DBP expo-
sure (Heger et al., 2012; van den Driesche et al., 2015a). Thisatoxylin; scale bar corresponds to 50 mm. Bottom: triple immunofluorescence
rom three fetuses was investigated.
fted into castrated nude mice. Seminal vesicle weight calculated as a ratio
etermined by RIA. Values represent means ± SEMs, with n = 3.
er of OCT4+ and MAGE-A4+ cells. Values represent means ± SEMs, with n = 3.
lls/(OCT4+ + MAGE-A4+ cells). Values represent means ± SEMs, with n = 3.
supports the concept that the disruption of Nodal and Activin
signaling in the human fetal testis contributes to a testicular
dysgenesis syndrome phenotype. However, the complete
testicular dysgenesis that is observed after experimental inhibi-
tion of Nodal and Activin signaling in first trimester fetal testes
constitute a more severe phenotype than the focal disruption
that is most often observed in testicular tissue from adult pa-
tients with testicular dysgenesis syndrome (Hoei-Hansen et al.,
2003; Rajpert-De Meyts et al., 2013), making direct comparison
of the consequent effects on germ cells difficult.
Separating the roles of Nodal signaling and Activin signaling in
first trimester human fetal testes development by individually
stimulating and inhibiting each signaling pathway clearly demon-
strated that these two pathways have distinct but partly overlap-
ping roles during human fetal testis development. The opposing
effects of Nodal and Lefty treatment on the number of OCT4+
gonocytes indicate that the Nodal pathway is a direct regulator
of the expression of pluripotency factors in the human fetal
testis. Because the expression ofCripto is triggered by fibroblast
growth factor 9 (FGF9) in fetal mouse testes, resulting in the initi-
ation of signaling through the Nodal pathway (Spiller et al., 2012),
it would be relevant to examine the involvement of the FGF9
pathway in human fetal testis development in future studies.
The other distinct finding of our study implicating Nodal signaling
in the establishment of seminiferous cords is most likely an indi-
rect effect. In mice, disruption of seminiferous cords was also
evident following the simultaneous inhibition of Nodal and Activin
signaling (Wu et al., 2013; Miles et al., 2013). The formation and
organization of seminiferous cords in mice is known to depend
on endothelial cell migration from the mesonephros, with disrup-
ted cord formation observed after inhibition of the migration of
these cells, but without effects on Sertoli cell expression of
SOX9 (Combes et al., 2009). These findings closely resemble
the phenotype observed in human testes in the present study
and suggest that the Nodal pathway could also be involved in
regulating endothelial cell migration in early testicular organo-
genesis in humans, although this remains to be elucidated. The
reduced number of OCT4+ gonocytes resulting from the inhibi-
tion of Nodal signaling may also involve indirect effects in addi-
tion to the direct regulation of pluripotency factor expression,
because the disrupted seminiferous cords result in impaired
germ cell-somatic niche interaction, which is likely to also affect
gonocyte survival and proliferation. Because there was also a
reduced number of gonocytes in follistatin-treated samples, it in-
dicates that both Nodal and Activin are involved in germ cell sur-
vival and proliferation. This is in accordance with a previous
study showing that Activin A stimulates human oogonial survival
(Martins da Silva et al., 2004) and the notion that also TGF-b and
GDFmediates signals through ALK4/5/7, which could contribute
to the more severe effects of SB431542 compared to Lefty and
follistatin treatments. Moreover, the complete loss of gonocytes
observed in second trimester fetal testes following the simulta-
neous inhibition of Nodal and Activin indicates that the effect
of Nodal inhibition is a direct effect because the seminiferous
cords were not disrupted in these samples. Specific inhibition
of the Nodal pathway by Lefty treatment in first trimester fetal
testes resulted in effects on the somatic cells and seminiferous
cords that resembled the effects of simultaneous inhibition ofNodal and Activin, with seminiferous cords almost completely
disrupted and a clear reduction in Sertoli cell AMH immunoex-
pression, although the secretion of AMH to the media of
ex vivo cultures was not affected. Also, inhibition of Nodal and
Activin pathways separately did not appear to affect the fetal
Leydig cells, since no effects on steroidogenesis or expression
of CYP11A1 were observed, perhaps indicating some redun-
dancy between these signaling pathways in the regulation of
fetal Leydig cell function.
Stimulation of Nodal signaling in first trimester fetal testes
distinctly increased the number of OCT4+ gonocytes, and a
similar effect was found in second trimester fetal testes in which
the expression of pluripotency factors is normally downregulated
as part of the transition from gonocyte to pre-spermatogonium.
The effects of short-term stimulation of the Nodal pathway in cul-
ture persisted for up to 6 weeks after xenografting, indicating
that the physiological regulation of gonocyte to pre-spermato-
gonia transition in human fetal testes may involve Nodal
signaling. This finding has implications for our understanding of
the first step in the development of testicular GCNIS, which are
considered to be arrested fetal gonocytes persisting within the
testis (Rajpert-De Meyts et al., 2016; Skakkebaek et al., 1987).
The current model for the pathogenesis of testicular germ cell
cancer proposes that the arrest of fetal gonocyte differentiation
is the result of altered signaling from the surrounding somatic
cells, including in particular reduced androgen stimulation and
testicular dysgenesis (Skakkebaek et al., 2001; Rajpert-De
Meyts and Skakkebaek, 1993). In this study, we have demon-
strated reduced androgen production and complete disruption
of seminiferous cords in the first trimester fetal human testis
following SB431542-induced simultaneous inhibition of Nodal
and Activin signaling, but without any indication of an increased
number of gonocytes. The SB431542-induced widespread
dysgenesis and pronounced reduction in androgen production
did not lead to the arrest of gonocyte differentiation; rather,
this cell population was lost. Conversely, the stimulation of Nodal
signaling in first trimester fetal testis samples that resulted in an
increased number of gonocytes also caused an increase in the
production of androgen precursors. This is in contrast to the pro-
posed mechanism of reduced masculinization resulting in pro-
longed expression of pluripotency factors in human fetal gono-
cytes in the pathogenesis of testicular germ cell cancer.
Despite this, the finding of prolonged expression of OCT4 in hu-
man fetal gonocytes after the stimulation of Nodal signaling pro-
vides insight into a possible mechanism for the development of
the testicular cancer precursor GCNIS, which, based on the find-
ings in this study, could involve focal dysregulation of the Nodal
pathway. However, independent validation and further studies
are needed to corroborate this hypothesis.
In conclusion, the present study demonstrated a key role of
Nodal signaling in regulating the expression of pluripotency fac-
tors in human fetal germ cells and in the establishment of semi-
niferous cords during early human fetal testis development.
Moreover, we found that the Nodal and Activin signaling
pathways cooperate in mediating fetal germ cell survival and
proliferation as well as AMH secretion by immature Sertoli cells
and steroidogenesis by the fetal Leydig cells. The effects on
seminiferous cord structure and expression of somatic cellCell Reports 25, 1924–1937, November 13, 2018 1935
markers following the simultaneous inhibition of Nodal signaling
and Activin signaling were reversible, while the effects on germ
cells and steroidogenesis were not. The present study substan-
tially adds to the understanding of early events in human fetal
testis development. Our findings delineate the consequences
of dysregulating Nodal and Activin signaling in the human fetal
testis, which have important implications for understanding
male reproductive disorders, including in particular testicular
dysgenesis syndrome and the pathogenesis of germ cell
neoplasia.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Collection of human fetal gonads in Denmark
B Collection of human fetal gonads in UK
B Nude mice
d METHOD DETAILS
B Ex vivo testis tissue culture
B Grafting of human fetal testis tissue into nude mice
B Immunohistochemistry
B Immunofluorescence
B BrdU incorporation
B Quantification of germ cells
B TUNEL assay
B Quantification of testosterone in mice
B Steroid hormone measurements in culture medium
B AMH measurements in culture medium
B Quantitative RT-PCR
d QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and three tables and can be
found with this article online at https://doi.org/10.1016/j.celrep.2018.10.064.
ACKNOWLEDGMENTS
The authors wish to thank the staff members at the Departments of Gynaecol-
ogy at Rigshospitalet and Hvidovre Hospital for their help with the collection of
the fetal tissue. The excellent technical assistance of the technicians at the
Department of Growth and Reproduction, especially Ana Ricci Nielsen, Ca-
milla Tang Thomsen, and Brian Vendelbo Hansen, is gratefully acknowledged.
We gratefully appreciate the work of Anne Saunderson and the staff of the
Bruntsfield Suite of the Royal Infirmary of Edinburgh for their provision of fetal
tissue, aswell as the HumanDevelopmental Biology Resource (www.hdbr.org)
for providing some of the fetal material (Joint MRC/Wellcome Trust grant no.
099175/Z/12/Z). We would also like to acknowledge WilliamMungall for assis-
tance with the animal work. We appreciate the kind gift of the FOXL2 antibody
from Dr. D. Wilhelm (University of Melbourne) and the MAGE-A4 antibody from
Prof. G. Spagnoli (University of Basel). This work was supported in part by a
European Society for Paediatric Endocrinology (ESPE) Research Fellowship,
sponsored by Novo Nordisk A/S, to A. Jørgensen. Additional funding for this
project was obtained from the Danish Cancer Society (grant no. R72-A4335-
13-S2, to A. Jørgensen), the Research Council of the Capital Region of
Denmark (to E.R.D.M.), a Wellcome Trust Intermediate Clinical Fellowship1936 Cell Reports 25, 1924–1937, November 13, 2018(grant no. 098522, to R.T.M.), The MRCCentre for Reproductive Health is sup-
ported by an MRC Centre Grant (MR/N022556/1). The Research Fund at
Rigshospitalet (to A. Juul and J.E.N.), The Erichssen Family Fund (to A. Jørgen-
sen), Dagmar Marshalls Fund (to A. Jørgensen), and the Aase & Ejnar Daniel-
sens Fund (to A. Jørgensen).
AUTHOR CONTRIBUTIONS
A. Jørgensen, E.R.D.M., andR.T.M. conceived the project. A. Jørgensen, J.M.,
J.E.N., K.R.K., and H.F. performed the experiments. L.L., S.P., L.L.T., and
K.J.H. provided the tissue. A. Jørgensen, A.-M.A., N.E.S., A. Juul, R.M.S.,
E.R.D.M., and R.T.M. analyzed and discussed the data. A. Jørgensen, A.
Juul, R.M.S., E.R.d.M., and R.T.M. wrote the manuscript. All of the authors
approved the submitted manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: May 21, 2018
Revised: September 14, 2018
Accepted: October 17, 2018
Published: November 13, 2018
REFERENCES
Bendsen, E., Byskov, A.G., Laursen, S.B., Larsen, H.P., Andersen, C.Y., and
Westergaard, L.G. (2003). Number of germ cells and somatic cells in human
fetal testes during the first weeks after sex differentiation. Hum. Reprod. 18,
13–18.
Berta, P., Hawkins, J.R., Sinclair, A.H., Taylor, A., Griffiths, B.L., Goodfellow,
P.N., and Fellous, M. (1990). Genetic evidence equating SRY and the testis-
determining factor. Nature 348, 448–450.
Combes, A.N., Wilhelm, D., Davidson, T., Dejana, E., Harley, V., Sinclair, A.,
and Koopman, P. (2009). Endothelial cell migration directs testis cord forma-
tion. Dev. Biol. 326, 112–120.
Corker, C.S., and Davidson, D.W. (1978). A radioimmunoassay for testos-
terone in various biological fluids without chromatography. J. Steroid Bio-
chem. 9, 373–374.
Cortes, D., Thorup, J., and Visfeldt, J. (2003). Multinucleated spermatogonia in
cryptorchid boys: a possible association with an increased risk of testicular
malignancy later in life? APMIS 111, 25–31.
Evtouchenko, L., Studer, L., Spenger, C., Dreher, E., and Seiler, R.W. (1996).
A mathematical model for the estimation of human embryonic and fetal age.
Cell Transplant. 5, 453–464.
Gaskell, T.L., Esnal, A., Robinson, L.L., Anderson, R.A., and Saunders, P.T.
(2004). Immunohistochemical profiling of germ cells within the human fetal
testis: identification of three subpopulations. Biol. Reprod. 71, 2012–2021.
Hanley, N.A., Hagan, D.M., Clement-Jones, M., Ball, S.G., Strachan, T., Salas-
Corte´s, L., McElreavey, K., Lindsay, S., Robson, S., Bullen, P., et al. (2000).
SRY, SOX9, and DAX1 expression patterns during human sex determination
and gonadal development. Mech. Dev. 91, 403–407.
Heger, N.E., Hall, S.J., Sandrof, M.A., McDonnell, E.V., Hensley, J.B.,
McDowell, E.N., Martin, K.A., Gaido, K.W., Johnson, K.J., and Boekelheide,
K. (2012). Human fetal testis xenografts are resistant to phthalate-induced
endocrine disruption. Environ. Health Perspect. 120, 1137–1143.
Hoei-Hansen, C.E., Holm, M., Rajpert-De Meyts, E., and Skakkebaek, N.E.
(2003). Histological evidence of testicular dysgenesis in contralateral biopsies
from 218 patients with testicular germ cell cancer. J. Pathol. 200, 370–374.
Hoei-Hansen, C.E., Nielsen, J.E., Almstrup, K., Sonne, S.B., Graem, N., Skak-
kebaek, N.E., Leffers, H., and Rajpert-DeMeyts, E. (2004). Transcription factor
AP-2gamma is a developmentally regulated marker of testicular carcinoma
in situ and germ cell tumors. Clin. Cancer Res. 10, 8521–8530.
Honecker, F., Stoop, H., de Krijger, R.R., Chris Lau, Y.F., Bokemeyer, C., and
Looijenga, L.H. (2004). Pathobiological implications of the expression of
markers of testicular carcinoma in situ by fetal germ cells. J. Pathol. 203,
849–857.
James, D., Levine, A.J., Besser, D., and Hemmati-Brivanlou, A. (2005).
TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripo-
tency in human embryonic stem cells. Development 132, 1273–1282.
Jørgensen, A., and Rajpert-De Meyts, E. (2014). Regulation of meiotic entry
and gonadal sex differentiation in the human: normal and disrupted signaling.
Biomol. Concepts 5, 331–341.
Jørgensen, N., Rajpert-De Meyts, E., Graem, N., M€uller, J., Giwercman, A.,
and Skakkebaek, N.E. (1995). Expression of immunohistochemical markers
for testicular carcinoma in situ by normal human fetal germ cells. Lab. Invest.
72, 223–231.
Jørgensen, A., Nielsen, J.E., Blomberg Jensen, M., Græm, N., and Rajpert-De
Meyts, E. (2012). Analysis of meiosis regulators in human gonads: a sexually
dimorphic spatio-temporal expression pattern suggests involvement of
DMRT1 in meiotic entry. Mol. Hum. Reprod. 18, 523–534.
Jørgensen, A., Nielsen, J.E., Almstrup, K., Toft, B.G., Petersen, B.L., and Raj-
pert-De Meyts, E. (2013). Dysregulation of the mitosis-meiosis switch in testic-
ular carcinoma in situ. J. Pathol. 229, 588–598.
Jørgensen, A., Young, J., Nielsen, J.E., Joensen, U.N., Toft, B.G., Rajpert-De
Meyts, E., and Loveland, K.L. (2014). Hanging drop cultures of human testis
and testis cancer samples: a model used to investigate activin treatment ef-
fects in a preserved niche. Br. J. Cancer 110, 2604–2614.
Jørgensen, A., Nielsen, J.E., Perlman, S., Lundvall, L., Mitchell, R.T., Juul, A.,
andRajpert-DeMeyts, E. (2015). Ex vivo culture of human fetal gonads: manip-
ulation of meiosis signalling by retinoic acid treatment disrupts testis develop-
ment. Hum. Reprod. 30, 2351–2363.
Li, L., Dong, J., Yan, L., Yong, J., Liu, X., Hu, Y., Fan, X., Wu, X., Guo, H., Wang,
X., et al. (2017). Single-Cell RNA-Seq Analysis Maps Development of Human
Germline Cells andGonadal Niche Interactions. Cell StemCell 20, 858–873.e4.
Martins da Silva, S.J., Bayne, R.A., Cambray, N., Hartley, P.S., McNeilly, A.S.,
and Anderson, R.A. (2004). Expression of activin subunits and receptors in the
developing human ovary: activin A promotes germ cell survival and prolifera-
tion before primordial follicle formation. Dev. Biol. 266, 334–345.
Miles, D.C., Wakeling, S.I., Stringer, J.M., van den Bergen, J.A., Wilhelm, D.,
Sinclair, A.H., andWestern, P.S. (2013). Signaling through the TGF beta-activin
receptors ALK4/5/7 regulates testis formation and male germ cell develop-
ment. PLoS One 8, e54606.
Mitchell, R.T., Cowan, G., Morris, K.D., Anderson, R.A., Fraser, H.M., Mcken-
zie, K.J., Wallace, W.H., Kelnar, C.J., Saunders, P.T., and Sharpe, R.M. (2008).
Germ cell differentiation in the marmoset (Callithrix jacchus) during fetal and
neonatal life closely parallels that in the human. Hum. Reprod. 23, 2755–2765.
Mitchell, R.T., Saunders, P.T., Childs, A.J., Cassidy-Kojima, C., Anderson,
R.A., Wallace, W.H., Kelnar, C.J., and Sharpe, R.M. (2010). Xenografting of hu-
man fetal testis tissue: a new approach to study fetal testis development and
germ cell differentiation. Hum. Reprod. 25, 2405–2414.
Ostrer, H., Huang, H.Y., Masch, R.J., and Shapiro, E. (2007). A cellular study of
human testis development. Sex Dev. 1, 286–292.
Papanayotou, C., and Collignon, J. (2014). Activin/Nodal signalling before im-
plantation: setting the stage for embryo patterning. Philos. Trans. R. Soc.
Lond. B Biol. Sci. 369, 1657.
Pauls, K., Schorle, H., Jeske, W., Brehm, R., Steger, K., Wernert, N., B€uttner,
R., and Zhou, H. (2006). Spatial expression of germ cell markers during matu-
ration of human fetal male gonads: an immunohistochemical study. Hum.
Reprod. 21, 397–404.Rajpert-De Meyts, E., and Hoei-Hansen, C.E. (2007). From gonocytes to
testicular cancer: the role of impaired gonadal development. Ann. NY Acad.
Sci. 1120, 168–180.
Rajpert-De Meyts, E., and Skakkebaek, N.E. (1993). The possible role of sex
hormones in the development of testicular cancer. Eur. Urol. 23, 54–61.
Rajpert-De Meyts, E., Hanstein, R., Jørgensen, N., Graem, N., Vogt, P.H., and
Skakkebaek, N.E. (2004). Developmental expression of POU5F1 (OCT-3/4) in
normal and dysgenetic human gonads. Hum. Reprod. 19, 1338–1344.
Rajpert-De Meyts, E., Almstrup, K., and Skakkebaek, N.E. (2013). Testicular
dysgenesis syndrome and carcinoma in situ testis. In Atlas on the Human
Testis, D. Jezek, ed. (Springer-Verlag), pp. 159–178.
Rajpert-De Meyts, E., McGlynn, K.A., Okamoto, K., Jewett, M.A., and Boke-
meyer, C. (2016). Testicular germ cell tumours. Lancet 387, 1762–1774.
Rotgers, E., Jørgensen, A., and Yao, H.H. (2018). At the crossroads of fate-so-
matic cell lineage specification in the fetal gonad. Endocr. Rev. 39, 739–759.
Sinclair, A.H., Berta, P., Palmer, M.S., Hawkins, J.R., Griffiths, B.L., Smith,
M.J., Foster, J.W., Frischauf, A.M., Lovell-Badge, R., and Goodfellow, P.N.
(1990). A gene from the human sex-determining region encodes a protein
with homology to a conserved DNA-binding motif. Nature 346, 240–244.
Skakkebaek, N.E., Berthelsen, J.G., Giwercman, A., andM€uller, J. (1987). Car-
cinoma-in-situ of the testis: possible origin from gonocytes and precursor of all
types of germ cell tumours except spermatocytoma. Int. J. Androl. 10, 19–28.
Skakkebaek, N.E., Rajpert-De Meyts, E., and Main, K.M. (2001). Testicular
dysgenesis syndrome: an increasingly common developmental disorder with
environmental aspects. Hum. Reprod. 16, 972–978.
Skakkebaek, N.E., Rajpert-DeMeyts, E., Buck Louis, G.M., Toppari, J., Ander-
sson, A.M., Eisenberg, M.L., Jensen, T.K., Jørgensen, N., Swan, S.H., Sapra,
K.J., et al. (2016). Male reproductive disorders and fertility trends: influences of
environment and genetic susceptibility. Physiol. Rev. 96, 55–97.
Søeborg, T., Frederiksen, H., Johannsen, T.H., Andersson, A.M., and Juul, A.
(2017). Isotope-dilution TurboFlow-LC-MS/MS method for simultaneous
quantification of ten steroid metabolites in serum. Clin. Chim. Acta 468,
180–186.
Souquet, B., Tourpin, S., Messiaen, S., Moison, D., Habert, R., and Livera, G.
(2012). Nodal signaling regulates the entry into meiosis in fetal germ cells.
Endocrinology 153, 2466–2473.
Spiller, C.M., Feng, C.W., Jackson, A., Gillis, A.J., Rolland, A.D., Looijenga,
L.H., Koopman, P., and Bowles, J. (2012). Endogenous Nodal signaling regu-
lates germ cell potency during mammalian testis development. Development
139, 4123–4132.
Spiller, C., Burnet, G., and Bowles, J. (2017). Regulation of fetal male germ cell
development by members of the TGFb superfamily. Stem Cell Res. 24,
174–180.
van den Driesche, S., McKinnell, C., Calarr~ao, A., Kennedy, L., Hutchison,
G.R., Hrabalkova, L., Jobling, M.S., Macpherson, S., Anderson, R.A., Sharpe,
R.M., and Mitchell, R.T. (2015a). Comparative effects of di(n-butyl) phthalate
exposure on fetal germ cell development in the rat and in human fetal testis
xenografts. Environ. Health Perspect. 123, 223–230.
van den Driesche, S., Macdonald, J., Anderson, R.A., Johnston, Z.C., Chetty,
T., Smith, L.B., Mckinnell, C., Dean, A., Homer, N.Z., Jorgensen, A., et al.
(2015b). Prolonged exposure to acetaminophen reduces testosterone produc-
tion by the human fetal testis in a xenograft model. Sci. Transl. Med. 7,
288ra80.
Wu, Q., Kanata, K., Saba, R., Deng, C.X., Hamada, H., and Saga, Y. (2013).
Nodal/activin signaling promotes male germ cell fate and suppresses female
programming in somatic cells. Development 140, 291–300.Cell Reports 25, 1924–1937, November 13, 2018 1937
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-OCT3/4 (C-10) Santa Cruz Sc-5279; RRID: AB_628051
Goat polyclonal anti-NANOG R&D Systems AF-1997; RRID: AB_355097
Mouse monoclonal anti-AP2g (6E4/4) Santa Cruz Sc-12762; RRID: AB_667770
Mouse monoclonal anti-SALL4 (EE-30) Santa Cruz Sc-101147; RRID: AB_1129262
Goat polyclonal anti-LIN28A R&D Systems AF-3757; RRID: AB_2234537
Rabbit polyclonal anti-C-KIT (CD117) Dako A4502; RRID: AB_2335702
Mouse monoclonal anti-MAGE-A4 Non-commercial Gift from Prof. Spagnoli
Goat polyclonal anti-AMH (MIS, C-20) Santa Cruz Sc-6886; RRID: AB_649207
Rabbit polyclonal anti-SOX9 Millipore AB5535; RRID: AB_2239761
Rabbit monoclonal anti-cPARP Cell Signaling 5625; RRID: AB_10699460
Mouse monoclonal anti-BrdU Dako M0744; RRID: AB_10013660
Mouse monoclonal anti-COUP-TFII (H7147) Perseus Proteomics PP-H7147-60; RRID: AB_2314222
Rabbit polyclonal anti-CYP11A1 Sigma HPA016436; RRID: AB_1847423
Mouse monoclonal anti-gH2A.X (phosho S139)(9F3) Abcam Ab26350; RRID: AB_470861
Rabbit polyclonal anti-SCP3 Novus NB300-232; RRID: AB_2087193
Rabbit polyclonal anti-VASA (DDX4) Abcam Ab13840; RRID: AB_443012
Rabbit polyclonal anti-FOXL2 Non-commercial Gift from Prof. Wilhelm
Rabbit polyclonal anti-DMRT1 Sigma HPA027850; RRID: AB_10600868
Biological Samples
Human fetal testis and ovary tissue Copenhagen University Hospital Department Growth and Reproduction fetal
tissue collection. Permit H-1-2012-007
Human fetal testis tissue Edinburgh University Centre for Reproductive Health fetal tissue
collection. Permit LREC08/S1101/1
Chemicals, Peptides, and Recombinant Proteins
SB431542 Sigma-Aldrich S4317
Recombinant Nodal R&D Systems 3218-ND-025
Recombinant Lefty R&D Systems 746-LF-025
Recombinant Activin A R&D Systems 338-AC-010
Recombinant Follistatin R&D Systems 669-FO-025
Experimental Models: Organisms/Strains
Male CD1 nude mice Charles River UK, Margate, England Crl-CD1-Foxn1nu
Oligonucleotides
See Table S3 for primer details N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Anne
Jørgensen (aj@rh.regionh.dk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Collection of human fetal gonads in Denmark
Human fetal gonads were isolated from material available following elective termination of pregnancy during the first trimester at the
Department of Gynaecology at Copenhagen University Hospital (Rigshospitalet) and Hvidovre Hospital, Denmark. The regional
ethics committee approved this study (permit number H-1-2012-007, including amendments 48801, 50662 and 55184) and womene1 Cell Reports 25, 1924–1937.e1–e4, November 13, 2018
gave their informed written and oral consent. None of the terminations were for reasons of fetal abnormality and all fetuses appeared
morphologically normal. The fetuses were between gestational week (GW) 7 and 12, with fetal age determined by scanning crown-
rump length and by evaluation of foot length (Evtouchenko et al., 1996). Fetal testis/mesonephros tissue was dissected in ice-cold
PBS and immediately set-up in ex vivo cultures. Testis tissue from 54 male fetuses was used for ex vivo culture followed by formalin
fixation. Tissue from 9 male fetuses were fixed immediately and used as age-matched controls (some of which were also used in a
previous study, Jørgensen et al., 2015). Finally, gonads from 11 male and 14 female fetuses were snap-frozen and used for inves-
tigation of gene expression. This corresponded to gonadal tissue from 79 fetuses in total.
Collection of human fetal gonads in UK
First-trimester (8-12 GW) and second-trimester (13–20 GW) human fetal testes were obtained following termination of pregnancy.
Women gave written informed consent in accordance with national guidelines and ethical approval was obtained from the Lothian
Research Ethics Committee (LREC08/S1101/1). No terminations were related to fetal abnormalities. In addition, fetal tissue was pro-
vided by the Human Developmental Biology Resource (www.hdbr.org). After dissection, the fetal testis was placed immediately into
ice-cold media containing Liebowitz L-15 with glutamine, 10% fetal bovine serum, 1% penicillin/streptomycin and 1% non-essential
amino acids (all Sigma, Poole, UK) before ex vivo culture and xenografting. Tissue from 3 male 1st trimester and 5 male 2nd trimester
fetuses were used for hanging drop ex vivo culture followed by xenografting, while 7 testes from 1st trimester and 15 testes from 2nd
trimester fetuses were used for gene expression analysis. This corresponded to gonadal tissue from 30 fetuses in total.
Nude mice
Xenografting was performed according to the Animal (Scientific Procedures) Act 1986 following specific approval by UKHomeOffice
and animals were maintained in accordance with UK Home Office guidelines under project license number PPL60/4654. Male CD1-
nude mice (aged 6-8 weeks, n = 38, Charles River UK, Margate, England) were used for experiments. Mice received analgesia
(Rimadyl LA, Pfizer, NY, USA) and antibiotics (Baytril, Bayer, Germany) in the drinking water for 5 days post-surgery.
METHOD DETAILS
Ex vivo testis tissue culture
Fetal testes were cultured ex vivo in hanging drops as described previously with comparison of cultured tissue to pre-culture controls
and age-matched control (Jørgensen et al., 2015). In brief, fetal testis tissue (andmesonephros in 1st trimester samples) was cultured
in 40 ml medium for 6-14 days. Medium composition was: MEMa media supplemented with 1 3 MEM non-essential amino acids
(Invitrogen), 2 mM sodium pyruvate, 2 mM L-glutamine, 1 3 Insulin, Transferrin and Selenium (ITS) supplement, (Sigma-Aldrich),
13 Penicillin/Streptomycin, 10% Fetal Bovine Serum (FBS). All cell media and supplements were from GIBCO (Naerum, Denmark),
except ITS (Sigma-Aldrich, Broendby, Denmark). Gonads were cultured at 37C under 5%CO2 with complete medium change every
48 hr. In general, each testis/mesonephros (1st trimester) and testis (2nd trimester) was divided into approximately 1 mm3 pieces with
at least one piece from each testis used as vehicle control. Tissue fragments were cultured in medium containing the ALK4/5/7 in-
hibitor SB431542 (20 mM), recombinant Lefty (100 ng/ml), recombinant Nodal (50 ng/ml), recombinant Follistatin (100 ng/ml), recom-
binant Activin A (50 ng/ml) or vehicle (0.1%DMSO, 0.1%BSA in PBS or 0.1%BSA, 4 mMHCl in PBS). All recombinant proteins were
from R&D Systems while SB431542 was from Sigma-Aldrich.
Grafting of human fetal testis tissue into nude mice
Male CD1-nude mice were anesthetized by inhalation of isofluorane, castrated, and small pieces (1 mm3) of human testis tissue were
inserted subcutaneously under the dorsal skin using a 13G cancer implant needle (Popper and Sons, NY, USA) as previously
described (van den Driesche et al., 2015b). The human fetal testis tissue pieces had been cultured ex vivo for 6 or 10 days with
SB431542 (20 mM), Nodal (50 ng/ml) or vehicle control (0.1% DMSO or 0.1% BSA, 4 mM HCl in PBS) prior to grafting. Between
two and six testis tissue pieces from a single fetus were inserted on either side of the midline. After the 6 weeks grafting period
host mice were killed by cervical dislocation and blood obtained by cardiac puncture for measurement of testosterone. Seminal ves-
icles were removed and weighed, and xenografts were retrieved and weighed.
Immunohistochemistry
Gonadal tissue was fixed in formalin or Bouins fluid either immediately after dissection (and used as pre-culture or age-matched con-
trols), at the end of the ex vivo culture period or after xenografting. The fixed gonads were dehydrated, paraffin embedded and
sectioned (4 mm) using standard procedures. Immunohistochemistry was conducted as previously described for formalin fixed sam-
ples (Jørgensen et al., 2012). In brief, antigen retrieval was accomplished by microwaving the sections for 15 min in retrieval buffer.
Sections were then incubated with 2%non-immune goat serum (ZymedHistostain kit, San Francisco, CA, USA) or 0.5%milk powder
diluted in Tris buffered saline (TBS) to minimize cross-reactivity. Primary antibodies, dilutions, and retrieval buffers are listed in
Table S1. After 16 h of incubation at 4C and 1 h at room temperature, the sections were incubated with biotinylated goat anti-rabbitCell Reports 25, 1924–1937.e1–e4, November 13, 2018 e2
IgG (Zymed Histostain kit) or biotinylated goat anti-mouse IgG (1:400), before a peroxidase-conjugated streptavidin complex (Zymed
Histostain kit) was used as a tertiary layer. Visualization was performed with amino ethyl carbasole (AEC) (Invitrogen by Life Technol-
ogy, Frederick, MD, USA) yielding a red color and sections were counterstainedwithMayer’s hematoxylin. Immunohistochemistry on
Bouin’s fluid fixed samples was conducted as previously described (Mitchell et al., 2010). In brief, sections (4 mm) were subjected to
heat-induced antigen retrieval in 0.01 M citrate buffer (pH 6) in a pressure cooker and endogenous peroxidase was blocked with 3%
(v/v) H2O2 inmethanol for 30min. Between each step, sections werewashed in Tris-buffered saline (TBS). Sections were incubated in
appropriate normal serum diluted 1:5 with TBS containing 5% (w/v) bovine serum albumin (BSA) for 30min. Sections were incubated
overnight with primary antibody diluted in serum at 4C in a humidified chamber and then incubated for 30 min with the appropriate
ImmPRESS HRP (peroxidase) secondary antibody, diluted in normal serum. Visualization was performed using ImmPACT DAB
peroxidase (HRP) substrate (Vector Laboratories) yielding a brown color and sections were counterstained with Meyer’s hematoxylin
before mounting with Aquatex (Merck, Damstadt, Germany). For both protocols negative controls were included and processed
with the primary antibody replaced by the dilution buffer alone. None of the negative control slides showed staining. All sections
were initially evaluated on a Nikon Microphot-FXA microscope and then by scanning slides on a NanoZoomer 2.0 HT (Hamamatsu
Photonics, Herrsching am Ammersee, Germany) followed by analysis using the software NDPview version 1.2.36 (Hamamatsu
Photonics).
Immunofluorescence
Immunofluorescence was performed with Tris-buffered saline (TBS) washes (33 5 min) between each step and all incubations were
carried out in in a humidity box (Fisher Scientific, UK). Sections (4 mm) were dewaxed and rehydrated using standard procedures,
followed by heat-induced antigen retrieval (pressure cooker) in 0.01 M citrate buffer (pH 6) and peroxidase block in 3% (v/v) H2O2
in methanol for 30 min. Next, the sections were blocked in normal chicken serum (NCS; Biosera, Ringmer, UK) diluted 1:5 in TBS
containing 5% (w/v) BSA (NCS/TBS/BSA), followed by incubation with OCT4 antibody diluted 1:100 in NCS/TBS/BSA overnight
at 4C. The next day, sections were incubated with peroxidase-conjugated chicken anti-mouse secondary antibody (Santa Cruz),
diluted 1:200 in NCS/TBS/BSA for 30 min at room temperature (RT), and followed by incubation with Tyr-Cy3 (Perkin Elmer-TSA-
Plus Cyanine3 System; Perkin Elmer Life Sciences, Boston, MA, USA) according to manufacturer’s instructions. Before the next pri-
mary antibody dilution was added, the sections were again subjected to antigen retrieval by blocking in NCS/TBS/BSA and overnight
incubation at 4C with MAGE-A4 antibody diluted 1:200 in NCS/TBS/BSA. On the third day, slides were incubated with peroxidase-
conjugated chicken anti-mouse secondary antibody (Santa Cruz) diluted 1:200 in NCS/TBS/BSA for 30 min at RT, followed by incu-
bation with Tyr-Fluorescein (Perkin Elmer-TSA-Plus Fluorescein System; Perkin Elmer Life Sciences) according to manufacturer’s
instructions. Sections were again subjected to antigen retrieval followed by blocking in NCS/TBS/BSA and incubation with SOX9
antibody diluted 1:2500 in NCS/TBS/BSA overnight at 4C. Sections were then incubated with peroxidase-conjugated chicken
anti-rabbit secondary antibody (Santa Cruz), diluted 1:200 in NCS/TBS/BSA for 30 min at RT, followed by incubation with Tyr-Cy5
(Perkin Elmer-TSA-Plus Cyanine5 System; Perkin Elmer Life Sciences, Boston, MA, USA) according to manufacturer’s instructions.
Sections were counterstained with DAPI (Sigma) diluted 1:500 in TBS for 10 min. Finally, slides were mounted with Permafluor
(Thermo Scientific, UK) and fluorescent images captured using an Olympus BX61 microscope (Olympus).
BrdU incorporation
BrdU incorporation was used to determine the presence of proliferating germ cells just prior to the end of the ex vivo culture period as
previously described (Jørgensen et al., 2014; Jørgensen et al., 2015). In brief, BrdU labeling reagent (Life Technologies, Naerum,
Denmark) was diluted 1:100 in culture media and tissue fragments were placed in BrdU containing media for 6 hr. Tissue pieces
were then washed 2 times in PBS for 5 min followed by fixation and paraffin embedding as described above. BrdU was visualized
by immunohistochemistry using a BrdU antibody (Table S1) as described in the Immunohistochemistry section, with positively
stained cells considered as proliferating.
Quantification of germ cells
To evaluate the IHC staining quantitatively, the number of stained cells per area of tissue was counted. For each sample the entire
tissue section was counted. The area was measured using NDPview software (Hamamatsu Photonics, Herrsching am Ammersee,
Germany). Germ cells were identified based on OCT4 staining (gonocytes) and MAGE-A4 staining (pre-spermatogonia). Two inves-
tigators (AJø and JEN) evaluated all stainings.
TUNEL assay
Apoptosis/DNA fragmentation was detected using the terminal deoxynucleotidyl transferase (TdT)-mediated dNTP nick end labeling
(TUNEL) assay (Trevigen, Gaithersburg, MD, USA). A slightly modified version of the manufacturers protocol was applied, using AEC
instead of DAB. Sections were counterstained by brief immersion in Mayer’s hematoxylin. Positive controls were incubated with
TACS nuclease for 1.5 h at 37C to induce DNA strand breaks. Negative controls were incubated without TdT enzyme.e3 Cell Reports 25, 1924–1937.e1–e4, November 13, 2018
Quantification of testosterone in mice
Plasma testosterone levels in xenografted host mice were measured at termination by competitive radioimmunoassay using an
extraction-based in-house radioimmunoassay method described previously (Corker and Davidson 1978). Testosterone levels
were expressed as ng/ml and all samples analyzed in a single assay with three replicates. The detection limit was 45 pg/ml, and
the intra-assay coefficient of variation was 8%.
Steroid hormone measurements in culture medium
Analysis of androgen and corticosteroid levels in culture media from ex vivo culture was measured by a new and sensitive isotope-
dilution TurboFlow-LC-MS/MSmethod for simultaneous quantification of dehydroepiandrosterone sulfate (DHEAS),D4-androstene-
dione, testosterone, 17a-hydroxyprogesterone (17-OHP), progesterone, 11-deoxycortisol, cortisol, cortisone, corticosterone, and
estrone-sulfate (Søeborg et al., 2017). The following modifications were applied: calibration curves were prepared in culture media,
control samples were prepared by spiking with high and low concentration of steroids, and all collected media samples were diluted
four times in culturemedia prior to analysis. A few samples were reanalyzed for testosterone after additional sample dilution. Samples
were analyzed in 11 batches during summer/autumn of 2016. Each batch included standards for calibration curves, 20 unknown
samples, one blank and three pooled controls spikedwith steroid standards at low and high levels. The inter-day variation, expressed
as the relative standard deviation (RSD) was% 6% for all analytes at both spike levels except for (E1-S) in low spike level (22%). The
recovery was > 92% for all analytes at both spike levels. Additional details in Table S2.
AMH measurements in culture medium
AMH levels in culture media from ex vivo culture was measured by ELISA using the Beckman Coulter enzyme immunometric assay
Reagents Kit (Ref. B13127, lot no. 871046) and Calibrator kit (Ref. B13128, lot no. 789308) according to the manufacturers instruc-
tion, except that the lyophilized calibrators were reconstituted in culture media instead of water. Collected media samples were
diluted 1:10 in culture media prior to analysis, with additional sample dilution (1:20 and 1:50) necessary for approximately
40% and 10% of the samples, respectively. The detection limit of the AMH assay was 0.14 pmol/L and the inter-assay variation
was < 7.5% in the total measurement range.
Quantitative RT-PCR
Quantitative PCR was conducted using the Mx300P platform (Stratagene, Cedar Creek, TX, USA), as previously described (Jørgen-
sen et al., 2013) or the ABI 7900HT (Applied Biosystems). Gene expression was examined using specific primers (Table S3) that were
designed to span intron–exon boundaries and all amplicons were sequenced to verify specificity (Eurofins Genomics, Ebersberg,
Germany). Standard curve analysis and efficiency of amplification was established to confirm that slopes of the standard curves
were close to 3.3 (equivalent to 100% PCR efficiency or two-fold amplification per cycle). Changes in gene expression were quan-
tified using the 2-DDCtmethod. Expression levels were normalized toRPS29 expression and calculated as a ratio with fetal testes from
GW 7–9 set to 1.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was determined using GraphPad Prism Software. Data are presented as mean ± SEM. For cultured samples
Student’s paired (two-tailed) t test was used. If samples were not paired (Figure S1) Student’s unpaired (two-tailed) t test was used.
Asterisks indicate statistical significance with * p < 0.05, ** p < 0.01, *** p < 0.001. The number of replicates in each experimental
setting and statistical significance are specified in each figure legend.Cell Reports 25, 1924–1937.e1–e4, November 13, 2018 e4
